Daily Stock Analysis, NUVA, NuVasive Inc, priceseries

NuVasive Inc. Daily Stock Analysis
Stock Information
Open
55.68
Close
54.66
High
56.45
Low
54.56
Previous Close
55.78
Daily Price Gain
-1.12
YTD High
58.56
YTD High Date
Jan 21, 2022
YTD Low
47.03
YTD Low Date
Feb 24, 2022
YTD Price Change
0.16
YTD Gain
0.29%
52 Week High
72.61
52 Week High Date
Apr 29, 2021
52 Week Low
45.45
52 Week Low Date
Dec 20, 2021
52 Week Price Change
-8.11
52 Week Gain
-12.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 17. 2017
53.71
Nov 1. 2017
56.48
11 Trading Days
5.15%
Link
LONG
May 30. 2018
50.87
Jun 22. 2018
54.24
17 Trading Days
6.63%
Link
LONG
Jul 30. 2018
57.22
Aug 28. 2018
69.02
21 Trading Days
20.63%
Link
LONG
Nov 14. 2018
59.22
Dec 3. 2018
62.30
12 Trading Days
5.21%
Link
LONG
Apr 23. 2019
57.21
May 10. 2019
60.84
13 Trading Days
6.35%
Link
LONG
Jul 30. 2019
60.02
Aug 13. 2019
64.89
10 Trading Days
8.11%
Link
LONG
Apr 21. 2020
55.74
May 1. 2020
58.96
8 Trading Days
5.78%
Link
LONG
Dec 16. 2020
47.32
Jan 12. 2021
54.62
17 Trading Days
15.43%
Link
Company Information
Stock Symbol
NUVA
Exchange
NasdaqGS
Company URL
http://www.nuvasive.com
Company Phone
(858) 909-1800
CEO
Gregory T. Lucier
Headquarters
California
Business Address
7475 LUSK BLVD., SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001142596
About

NuVasive, Inc. engages in the development and provision of medical devices. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Description

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to hospitals, surgeons, and other customers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.